Loading people...
Kevin Slawin is the Founder and Managing Partner of Rapha Capital Management and the Founder and CEO of Ponce Therapeutics, based in Miami, Florida. A former urologic oncologist who earned his medical degree from Columbia University, he transitioned into venture capital after founding Bellicum Pharmaceuticals and leading the biotechnology company to a $161 million initial public offering in December 2014. Slawin previously served as the interim CEO of AsclepiX Therapeutics, where he successfully engineered a $35 million Series A funding round led by the Perceptive Xontogeny Venture Fund in mid-2020. Through Rapha Capital, he currently manages 13 legacy special purpose investment vehicles and serves on the corporate boards of portfolio companies including 3DBio Therapeutics and FIZE Medical. His current professional focus centers on funding and developing early-stage biotechnology, oncology, medical devices, and longevity therapeutics.
Kevin Slawin stands as a distinguished figure in the venture capital landscape, currently serving as the Managing Partner at Rapha Capital Management. His leadership at Rapha Capital is instrumental in guiding the firm's strategic investments within the dynamic and critical sectors of life sciences, biotechnology, and healthcare. Slawin's unique value proposition stems from his profound medical background, which provides an invaluable lens through which to evaluate potential innovations and market opportunities.
Before embarking on his impactful career in investment, Dr. Slawin established himself as a highly respected medical professional. He earned his medical degree and completed extensive training, specializing in oncology. His clinical practice and research endeavors focused on understanding and treating complex diseases, particularly in the realm of cancer. This hands-on experience at the forefront of medical science equipped him with an intimate understanding of unmet medical needs, the challenges of drug development, and the potential for truly transformative therapies. This deep clinical insight is a cornerstone of his investment philosophy, allowing him to discern scientific merit and commercial viability with exceptional clarity.
At Rapha Capital Management, Kevin Slawin champions an investment strategy deeply rooted in scientific rigor and patient impact. The firm, under his guidance, targets early-stage and growth-stage companies developing groundbreaking technologies in areas such as novel therapeutics, diagnostics, medical devices, and digital health solutions. His particular interest often lies in oncology, rare diseases, and other high-impact therapeutic areas where his clinical expertise can best inform investment decisions. He seeks out companies poised to disrupt existing paradigms, improve patient outcomes, and address significant global health challenges.
Slawin's career trajectory from a practicing physician to a leading venture capitalist highlights his commitment to advancing healthcare beyond the clinic. He leverages his extensive network within the medical and scientific communities to identify promising ventures and provides strategic guidance to portfolio companies, helping them navigate the complex regulatory and commercial landscapes. His leadership ensures that Rapha Capital Management not only seeks financial returns but also contributes meaningfully to the progression of medical science and the betterment of human health.
Through Rapha Capital Management, Kevin Slawin continues to play a pivotal role in fostering innovation within the life sciences ecosystem. His vision is to support the development of therapies and technologies that have the potential to save lives and significantly enhance quality of life for patients worldwide. His blend of medical expertise, strategic insight, and investment acumen makes him a formidable and respected force in the biotech investment community, driving forward the next generation of medical breakthroughs.
Kevin Slawin is the Managing Partner at Rapha Capital Management, a venture capital firm focused on life sciences, biotechnology, and healthcare. He is also a former medical doctor specializing in oncology, bringing deep clinical expertise to his investment decisions.
Kevin Slawin primarily invests in early-stage and growth-stage companies within the life sciences, biotechnology, and healthcare sectors through Rapha Capital Management. His focus areas often include novel therapeutics, diagnostics, medical devices, and digital health, with a particular interest in oncology and rare diseases.
Kevin Slawin works as the Managing Partner at Rapha Capital Management, a venture capital firm.
